<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[okomera]]></title><description><![CDATA[okomera]]></description><link>https://www.okomera.com/blog</link><generator>RSS for Node</generator><lastBuildDate>Tue, 15 Sep 2026 21:08:01 GMT</lastBuildDate><atom:link href="https://www.okomera.com/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[From biopsy to treatment insight: how Okomera turns limited biology into actionable data]]></title><description><![CDATA[Okomera’s platform combines microfluidics, miniaturized tumor avatars and AI-driven imaging to generate treatment-response insights directly from patient-derived samples. In oncology, biological material is often limited. A patient biopsy can be small, fragile and difficult to work with. Yet this material contains valuable information about how a tumor may respond to treatment. Okomera’s technology is designed to unlock that information. The platform starts with a patient-derived biopsy....]]></description><link>https://www.okomera.com/post/from-biopsy-to-treatment-insight-how-okomera-turns-limited-biology-into-actionable-data</link><guid isPermaLink="false">6a562eec68b728cc93ff4afe</guid><category><![CDATA[News & Events]]></category><pubDate>Tue, 14 Jul 2026 12:43:42 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_208f7f64e21d47a2a49fb251f4fc0f4e~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[Why tumor response could become a new decision-making signal in oncology]]></title><description><![CDATA[Functional precision oncology offers a new way to support treatment decisions by observing how a patient’s own tumor responds to therapy, rather than relying only on historical data or molecular assumptions. Personalized cancer care has made significant progress over the past decade, particularly through molecular profiling and targeted therapies. Yet one of the central challenges in oncology remains: knowing which treatment will work best for a specific patient, at a specific point in time....]]></description><link>https://www.okomera.com/post/why-tumor-response-could-become-a-new-decision-making-signal-in-oncology</link><guid isPermaLink="false">6a562eb3119f6e25a1e1f863</guid><category><![CDATA[Scientific publications]]></category><pubDate>Tue, 14 Jul 2026 12:42:42 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_034977d095284715800f27a63b56f755~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item><item><title><![CDATA[BFM Business hosts Okomera CEO Silvère Lucquin]]></title><description><![CDATA[Okomera CEO Silvère Lucquin joined BFM Business to discuss how functional precision oncology can help transform cancer care by making tumor response data more accessible, actionable and clinically relevant. Okomera CEO Silvère Lucquin was featured on BFM Business to share the company’s vision for the future of cancer treatment and the role of functional precision oncology in transforming clinical decision-making. Today, cancer care still faces a major challenge: many patients do not respond...]]></description><link>https://www.okomera.com/post/bfm-business-hosts-okomera-ceo-silv%C3%A8re-lucquin</link><guid isPermaLink="false">6a562e70119f6e25a1e1f7a2</guid><pubDate>Tue, 14 Jul 2026 12:41:52 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/8bd814_b4acacdc02a04bfab8a5625d44cbf65f~mv2.jpg/v1/fit/w_1000,h_628,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator></dc:creator></item></channel></rss>